Avalo Therapeutics Quarterly Balance Sheet
NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Avalo Therapeutics financial position
As of Jun 30, 2026, Avalo Therapeutics reported total assets of $490.8 million, up 287.7% from a year earlier against total liabilities of $42.1 million. Shareholders' equity stood at $448.7 million, or 91.4% of assets. The company held $85.4 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 19.31, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Avalo Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 85.38M | 24.99M | 15.86M | 26.96M | 42.29M | 125.05M | 134.55M | 81.86M | 93.43M | 110.18M | 7.42M | 10.18M |
| Short-Term Investments | 314.89M | 57.01M | 82.48M | 84.65M | 70.97M | — | 0 | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Total Current Assets | 407.93M | 88.83M | 105.29M | 113.85M | 115.19M | 126.94M | 138.89M | 86.15M | 95.89M | 111.21M | 8.39M | 12.66M |
| Goodwill | 10.50M | 10.50M | 10.50M | 10.50M | 10.50M | 10.50M | 10.50M | 10.50M | 10.50M | 10.50M | 10.50M | 14.41M |
| Long-Term Investments | 71.88M | — | 0 | — | — | — | — | — | — | — | — | — |
| Total Assets | 490.78M | 99.89M | 116.46M | 125.10M | 126.58M | 138.52M | 150.73M | 98.45M | 108.31M | 123.73M | 20.99M | 29.27M |
| Accounts Payable | 3.35M | 356.00K | 137.00K | 474.00K | 2.37M | 681.00K | 283.00K | 1.81M | 654.00K | 916.00K | 446.00K | 789.00K |
| Total Current Liabilities | 21.13M | 11.60M | 12.94M | 7.97M | 9.26M | 5.62M | 6.96M | 60.67M | 96.40M | 215.70M | 4.62M | 6.00M |
| Long-Term Debt | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Total Liabilities | 42.12M | 31.57M | 33.41M | 33.55M | 22.01M | 15.91M | 17.70M | 75.72M | 110.46M | 224.81M | 13.69M | 14.57M |
| Shareholders' Equity | 448.66M | 68.32M | 83.05M | 91.55M | 104.57M | 122.61M | 133.03M | 21.08M | -13.61M | -112.54M | 7.30M | 14.70M |
| Retained Earnings | -504.51M | -468.15M | -448.52M | -434.80M | -404.18M | -383.41M | -370.26M | -334.92M | -357.96M | -456.42M | -335.13M | -326.97M |
| Total Debt | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Net Cash (Debt) | 400.28M | 81.99M | 98.34M | 111.62M | 113.26M | 125.05M | 134.55M | 81.86M | 93.43M | 110.18M | 7.42M | 10.18M |
| Shares Outstanding | 52.90M | 24.64M | 18.51M | 17.83M | 10.84M | 10.83M | 10.47M | 9.68M | 1.03M | 1.03M | 801.75K | 192.38M |
This table shows 12 quarterly periods of Avalo Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow AVTX's reporting calendar. What is a balance sheet?